Group 1 - The football concept sector rose by 3.56%, ranking fourth among concept sectors, with 21 stocks increasing in value [1] - Notable gainers included Jinling Sports, which hit a 20% limit up, and other stocks like Gongchuang Turf, Kangliyuan, and Yue Media, which rose by 20%, 12.98%, and 6.86% respectively [1][2] - Major decliners in the sector included SAIC Motor, Hikvision, and Shanghai Port Group, which fell by 5.86%, 0.32%, and 0.17% respectively [1] Group 2 - The football concept sector attracted a net inflow of 6.6248 million yuan, with 14 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2] - Yue Media led the net inflow with 92.989 million yuan, followed by Mongcao Ecology, Jinling Sports, and Zhongti Industry with net inflows of 56.7281 million yuan, 34.4254 million yuan, and 28.4689 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Gongchuang Turf, Mongcao Ecology, and Yue Media had the highest ratios at 19.83%, 17.24%, and 14.22% respectively [3] - The top stocks in the football concept sector based on net inflow included Yue Media with a 6.86% increase and a turnover rate of 9.69%, Mongcao Ecology with a 4.60% increase and a turnover rate of 5.65%, and Jinling Sports with a 20.00% increase and a turnover rate of 22.93% [3][4]

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 同花顺果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 | 3.08 | 一体化压铸 | -0.21 | | 眼科医疗 | 3.08 | 硅能源 | -0.18 | 资金面上看，今日医疗废物处理概念板块获主力资金净流出2.26亿元，其中，24股获主力资金净流出， 6股主力资金净流出超千万元，净流出资金居首的是东方园林，今日主力资金净流出9632.65万元，净流 出资金居前的还有玉禾田、圣元环保、现代投资等，主力资金分别 ...

截至6月3日收盘，同花顺果指数概念下跌0.41%，位居概念板块跌幅榜前列，板块内，闻泰科技、珠海 冠宇、鹏鼎控股等跌幅居前，股价上涨的有5只，涨幅居前的有东山精密、中石科技、歌尔股份等，分 别上涨1.03%、0.46%、0.14%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 同花顺果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 | 3.08 | 一体化压铸 | -0.21 | | 眼科医疗 | 3.08 | 硅能源 | -0.18 ...

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

细胞免疫治疗板块短线拉升，舒泰神（300204）涨超10%，雪榕生物（300511）、荣昌生物、金域医学 （603882）、莱美药业（300006）、和元生物等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, has received acceptance from the National Medical Products Administration (NMPA) for its cell immunotherapy product, Brexucabtagene Autoleucel (Ruxolitinib Injection), for a new indication in the second-line treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) patients [1][2] Group 1 - The application for Brexucabtagene Autoleucel is the fourth submission for this product by WuXi Biologics [1] - The NMPA granted breakthrough therapy designation for Brexucabtagene Autoleucel in January 2025 for the second-line treatment of r/r LBCL [1] - LBCL is a highly aggressive form of non-Hodgkin lymphoma and is the most common subtype of lymphoma in adults, with 30-40% of patients experiencing relapse or refractory disease after first-line treatment [1] Group 2 - The sBLA is based on a pivotal, single-arm, multi-center clinical study that evaluated Brexucabtagene Autoleucel in adult r/r LBCL patients who were not suitable for autologous stem cell transplantation (ASCT) after first-line treatment failure [2] - The Phase II open-label study in China included patients who had failed prior treatment with targeted CD20 antibodies and anthracycline-based regimens [2] - As of January 21, 2025, 49 patients had undergone cell infusion with at least 3 months of follow-up, showing significant clinical efficacy with an overall response rate (ORR) of 81.3% and a complete response rate (CRR) of 54.2% [2]

Group 1 - The military equipment restructuring concept has seen a decline of 1.73%, ranking among the top declines in the concept sector, with companies like Hunan Tianyan, Changcheng Military Industry, and Construction Industry experiencing significant drops [1] - The military equipment restructuring concept faced a net outflow of 177 million yuan from main funds today, with seven stocks experiencing net outflows, and five stocks seeing outflows exceeding 10 million yuan [2] - The stock with the highest net outflow is Changan Automobile, which saw a net outflow of 110 million yuan, followed by Changcheng Military Industry, Hunan Tianyan, and Construction Industry with net outflows of 16.49 million yuan, 15.59 million yuan, and 15.03 million yuan respectively [2] Group 2 - The top gainers in the concept sector today include medical waste treatment with a gain of 2.66%, and combustible ice with a gain of 2.50%, while the military equipment restructuring concept was among the top losers [2] - The trading volume for Changan Automobile was 0.68%, while Changcheng Military Industry had a turnover rate of 2.04%, and Hunan Tianyan had a turnover rate of 6.62% [2] - The military equipment restructuring concept includes several companies, with notable declines in stock prices, indicating a challenging market environment for this sector [1][2]

Group 1 - The core viewpoint of the news is that the China-South Korea Free Trade Zone concept has experienced a significant decline, with a drop of 3.07%, placing it among the top losers in the concept sector [1][2] - Within the China-South Korea Free Trade Zone concept, stocks such as Lianyungang and *ST Jinguang hit the daily limit down, while Qingdao King, Qingdao Port, and Rizhao Port saw notable declines [1][2] Group 2 - The China-South Korea Free Trade Zone concept faced a net outflow of 454 million yuan from major funds today, with 13 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Qingdao King, which saw a net outflow of 260 million yuan, followed by Lianyungang and Rizhao Port with net outflows of 115 million yuan and 29 million yuan, respectively [2]

Group 1 - The cell immunotherapy concept index rose by 1.35%, ranking third among concept sectors, with 35 stocks increasing in value, including Seer Medical which hit the daily limit, and Sunshine Nuohuo, Shutai Shen, and Betta Pharmaceuticals showing significant gains of 12.55%, 11.77%, and 8.35% respectively [1] - The concept sector saw a net inflow of 246 million yuan, with 29 stocks receiving net inflows, and 5 stocks attracting over 50 million yuan in net inflows, led by Huahai Pharmaceutical with a net inflow of 143 million yuan [1] - The top stocks by net inflow included Seer Medical, Huadong Medicine, and Saifutian, with net inflows of 126 million yuan, 106 million yuan, and 74 million yuan respectively [1] Group 2 - The leading stocks by net inflow ratio were Saifutian, Seer Medical, and Hai Xin Co., with net inflow ratios of 20.66%, 18.75%, and 15.23% respectively [2] - Huahai Pharmaceutical had a daily increase of 7.45% with a turnover rate of 7.28%, while Seer Medical increased by 10.04% with a turnover rate of 30.03% [2] - Other notable stocks included Betta Pharmaceuticals with an 8.35% increase and a turnover rate of 5.70%, and Rongchang Bio with a 2.08% increase and a turnover rate of 4.97% [2] Group 3 - Stocks with significant declines included Yaoji Technology, Hainan Hai Pharmaceutical, and Nearshore Protein, which fell by 4.24%, 3.62%, and 3.19% respectively [1] - The overall performance of the cell immunotherapy sector reflects a positive trend, with a majority of stocks experiencing gains, indicating investor confidence in this area [1][2] - The data suggests a strong interest from institutional investors in the cell immunotherapy sector, as evidenced by the substantial net inflows into key stocks [1][2]

Core Viewpoint - The company held its 2024 Annual General Meeting, discussing various operational and financial aspects, including a slight increase in revenue but a significant decrease in net profit, alongside strategic plans for future growth in various sectors [1][21][24]. Group 1: Meeting Details - The 2024 Annual General Meeting is scheduled for May 21, 2025, at 13:30 in Nanjing [1]. - The meeting will include both on-site and online voting methods [4]. - Legal opinions will be provided by Jiangsu Taihe Law Firm during the meeting [3][4]. Group 2: Financial Performance - The company achieved an operating revenue of 6.7 billion yuan, a year-on-year increase of 1.98%, with the main business revenue accounting for 95.91% [5][21]. - The net profit attributable to shareholders was 230 million yuan, a decrease of 46.10% compared to the previous year [21][24]. - The total assets of the company reached 26.225 billion yuan, with total liabilities of 7.132 billion yuan [23]. Group 3: Business Segments - The main business sectors include commercial retail, hospitality, health and elderly care, professional technical services, pharmaceutical manufacturing, and medical services [5][21]. - The commercial sector reported a revenue of 412 million yuan, down 11.27% year-on-year [22]. - The health and elderly care sector generated 2.128 billion yuan, with a slight decrease of 0.11% [22]. Group 4: Strategic Initiatives - The company is focusing on enhancing its core business capabilities and expanding its market presence in health and elderly care services, as well as in the biomedical sector [26][29]. - Plans include upgrading retail spaces and introducing new brands to improve customer experience [29]. - The company aims to retain undistributed profits for future investments in market expansion and R&D [31]. Group 5: Governance and Compliance - The board of directors held eight meetings during the reporting period, ensuring compliance with legal and regulatory requirements [9][12]. - The independent directors actively participated in decision-making and oversight, contributing to the company's stable development [14][15]. - The company has established a robust internal control system to manage operational risks effectively [16][20]. Group 6: Future Outlook - The company anticipates continued growth in the health and elderly care market, driven by an aging population and increasing consumer demand [25][27]. - The biomedical sector is expected to expand significantly, supported by government policies promoting stem cell technology and clinical applications [26][28]. - The retail business is undergoing transformation to adapt to market changes and consumer preferences, aiming for sustainable growth [29][31].